ANATOLY DRITSCHILO, M.D.
Radiology at Reservoir Rd, Washington, DC
License number
DC 11702
Category
Radiology
Type
Radiation Oncology
Address
Address
2
3800 Reservoir Rd NW, Washington, DC 20007
PO Box 418283, Boston, MA 02241
PO Box 418283, Boston, MA 02241
Phone
(202) 444-3320
(703) 558-1544
(703) 558-1544
Personal information
See more information about ANATOLY DRITSCHILO at radaris.comName
Address
Phone
3800 Reservoir Rd NW, Washington, DC 20007
Organization information
See more information about ANATOLY DRITSCHILO at bizstanding.comAnatoly Dritschilo
3800 Reservoir Rd NW, Washington, DC 20007
Industry:
Medical Doctor's Office, Nonclassifiable Establishments
Medical Doctor:
Antoly Dritschilo (Medical Doctor)
Moulds Jefferson Ec - Brian T Collins MD
3800 Reservoir Rd NW #LEVEL, Washington, DC 20007
Doing business as:
Moulds Jefferson Ec - Anatoly Dritschilo MD
Phone:
(202) 444-3320 (Phone)
Categories:
Physicians & Surgeons
Specialties:
Cancer, Military & Veteran's Services, Oncology, ...
Products:
Home Health Care, Military & Veteran's Services, Referrals
Professional information
Dr. Anatoly Dritschilo, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Radiology, Therapeutic Radiology
Address:
8101 Fenway Rd, Bethesda 20817
Certifications:
Therapeutic Radiology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
8101 Fenway Rd, Bethesda 20817
MedStar Georgetown University Hospital
3800 Reservoir Rd North #West, Washington 20007
MedStar Georgetown University Hospital
3800 Reservoir Rd North #West, Washington 20007
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1973
Cincinnati Genl Hosp
Harvard Joint Rad Ther Ctr
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1973
Cincinnati Genl Hosp
Harvard Joint Rad Ther Ctr
Anatoly Dritschilo, Washington DC
Specialties:
Pediatrics, Radiology, Therapeutic Radiology, Radiation Oncology
Work:
Medstar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC 20007
3800 Reservoir Rd NW, Washington, DC 20007
Education:
UMDNJ (1973)
Radiosurgery Methods That Utilize Stereotactic Methods To Precisely Deliver High Dosages Of Radiation Especially To The Spine
US Patent:
6665555, Dec 16, 2003
Filed:
Apr 5, 2001
Appl. No.:
09/826000
Inventors:
Fraser C. Henderson - Washington DC
James Rodgers - Washington DC
Azam Niroomand-Rad - Washington DC
Kevin Cleary - Washington DC
Anatoly Dritschilo - Washington DC
Leon Der - Washington DC
James Rodgers - Washington DC
Azam Niroomand-Rad - Washington DC
Kevin Cleary - Washington DC
Anatoly Dritschilo - Washington DC
Leon Der - Washington DC
Assignee:
Georgetown University School of Medicine - Washington DC
International Classification:
A61B 505
US Classification:
600427, 128899, 378 64, 378 65, 600425, 600473, 600476, 600 1, 600 2, 600 3
Abstract:
A system for delivery of high dosage of radiation to a targeted spinal area is provided. This is accomplished by a system which provides for precise immobilization and positioning of the treated spinal area during dose planning and treatment via stereotactic radiosurgery. Advantages of the system include convenience to the patient, enhanced efficacy, and reduced risk of radiotoxicity to non-target tissues.
The P65 Subunit Of Nf-Kb For The Radiosensitization Of Cells
US Patent:
2005028, Dec 29, 2005
Filed:
Feb 19, 2003
Appl. No.:
10/504364
Inventors:
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K039/00, A61K038/18
US Classification:
424185100, 514012000
Abstract:
The transcription factor NF-κB is activated in response to various stimuli including ionizing radiation. Disruption of NFκB activation by mutant forms of the NF-κB inhibitor IκB-α or by proteasome inhibitors enhances both sensitivity to radiation and radiation-induced apoptasis. The present invention shows that expression of a dominant negative fragment of human p65 (p65DN) leads to down-regulation of both endogenous p65 protein and its mRNA. The dominant negative protein also inhibits radiation-induced NF-κB activation by preventing the proteolysis of IκB-α, resulting in enhancement of cellular radiosensitivity and radiation-induced apoptosis. The region of p65 in the dominant negative fragment is thus a molecular target for disruption of NF-κB activation and sensitization of tumors to radiotherapy.
Gene Therapy For Prostate Cancer: Sensibilization Of Cells To Dna Damaging Drugs And Radiation
US Patent:
2004006, Apr 8, 2004
Filed:
Nov 20, 2003
Appl. No.:
10/450411
Inventors:
Viatcheslav Soldatenkov - Washington DC, US
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
International Classification:
A61K048/00, C07H021/04
US Classification:
514/044000, 536/023500, 435/320100
Abstract:
The present invention is directed to a novel therapeutic method for treating prostate cancer. The method employs the tissue-specific PSA promoter/enhancer as well as the unique properties of the DNA binding domain (dbd) of poly (ADP-ribose) polymerase (PARP) as a potent inhibitor of DNA damage repair and as a molecular sensitizer to genotoxic stresses. The sustained presence of the PARP-DBD in prostate tumor tissue induces enhanced tumor cell killing in response to DNA damaging treatments. The invention may be used as a biotherapeutic approach in the treatment of prostate cancers, which fail local-regional therapy, without significant risk of normal tissue damage.